Previous Article | Next Article 
Applied and Environmental Microbiology, February 1999, p. 640-647, Vol. 65, No. 2
0099-2240/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A Mutation That Improves Soluble Recombinant
Hemoglobin Accumulation in Escherichia coli in Heme
Excess
Michael J.
Weickert,*
Maria
Pagratis,
Christopher B.
Glascock, and
Richard
Blackmore
Baxter Hemoglobin Therapeutics, Inc.
(formerly Somatogen, Inc.), Boulder, Colorado
Received 29 June 1998/Accepted 4 November 1998
 |
ABSTRACT |
High-level expression of soluble recombinant human hemoglobin (rHb)
in Escherichia coli was obtained with several hemoglobin variants. Under identical conditions, two rHbs containing the Presbyterian mutation (Asn-108
Lys) in
-globin accumulated to approximately twofold less soluble globin than rHbs containing the
corresponding wild-type
-globin subunit accumulated. The
-globin
Providence(asp) mutation (Lys-82
Asp) significantly
improved soluble rHb accumulation compared to the wild-type
-globin
subunit and restored soluble accumulation of rHbs containing the
Presbyterian mutation to wild-type levels. The
Providenceasp substitution introduced a negatively charged
residue into the normally cationic 2,3-bisphosphoglycerate binding
pocket, potentially reducing the electrostatic repulsion in the absence
of the polyanion. The average soluble globin accumulation when there
was coexpression of di-
-globin and
-Lys-82
Asp-globin (rHb9.1)
and heme was present in at least a threefold molar excess was 36% ± 3% of the soluble cell protein in E. coli. The average total accumulation (soluble globin plus insoluble globin) was 56% ± 7% of the soluble cell protein. Fermentations yielded 6.0 ± 0.3 g of soluble rHb9.1 per liter 16 h after induction and
6.4 ± 0.2 g/liter 24 h after induction. The average total
globin yield was 9.4 g/liter 16 h after induction. High-level
accumulation of soluble rHb in E. coli depends on culture
conditions, the protein sequence, and the molar ratio of the heme
cofactor added.
 |
INTRODUCTION |
Unique among the hemoglobin-based
oxygen carriers currently undergoing clinical evaluation is rHb1.1, a
recombinant human hemoglobin (rHb) produced in Escherichia
coli. This hemoglobin contains two modifications that increase its
suitability as a hemoglobin-based oxygen carrier. The first
modification is a genetically linked di-
-globin molecule that
prevents dissociation of hemoglobin into 
dimers, thus reducing
renal filtration and extending the intravascular half-life (10,
18). And second, rHb1.1. contains the Presbyterian mutation
(Asn-108
Lys) (21) in
-globin which reduces the oxygen
affinity to a level roughly comparable to that of native
hemoglobin bound to 2,3-biphosphoglycerate (DPG). DPG naturally
modifies the oxygen affinity of native hemoglobin in erythrocytes.
Overproduction of a heterologous protein in E. coli is
especially challenging when the protein must be soluble and functional and is composed of multiple subunits. In addition, heterologous proteins like rHbs require the enhanced presence of essential cofactors
(prosthetic groups), such as heme and flavins, which occurs through
supplementation or increased endogenous production (reviewed in
reference 29). In E. coli, accumulation
of soluble rHb (11, 26), human cystathionine
-synthase
(12), rat cytochrome b5
(32), and Vitroscilla hemoglobin (VHb)
(9) is limited by heme availability, as indicated by the
fact that
-aminolevulinic acid, a heme precursor, is required to
increase heme and protein accumulation (12, 26, 32).
Insoluble VHb aggregates do not contain heme, suggesting that heme may
stabilize VHb and thus prevent aggregation (9).
High-level production of functional recombinant hemoglobin in
E. coli was achieved when there was concomitant
expression of both
-globin (or di-
-globin) and
-globin
subunits and exogenous heme was provided (10, 18).
Accumulation of soluble rHb1.1 in E. coli can account for as
much as 15% of the soluble cell protein when heme is added to the
culture medium (30). Production of rHb in E. coli
can also result in insoluble aggregate formation (10, 18,
28), which also occurs when many other recombinant proteins are
overexpressed in E. coli (reviewed in references 20 and 25). The presence of heme
in the globin protein is a major factor in partitioning of the globin
protein between soluble and insoluble fractions in vivo
(28). This is consistent with the hypothesis that an absence
of heme during globin chain biosynthesis results in insoluble
aggregates composed of partially folded apoprotein (20).
Removal of heme from human hemoglobin in vitro results in partial
unfolding and severely reduced solubility (16).
In addition to cofactors such as heme, the protein sequence can
influence aggregation. Aggregation of protein in vivo during bacterial
production is sometimes decreased by mutations which diminish the
kinetic trap of self-association of folding intermediates (reviewed in
references 13 and 31). Myoglobin
mutants which have high soluble protein yields also have relatively
stable apoproteins (8).
In the study described here we examined the effects of mutations and
heme concentration on soluble rHb accumulation. Our results indicate
that high-level accumulation of soluble rHb requires excess heme and
depends on the amino acid sequence of the globin protein itself.
Although the di-alpha linkage may slightly improve soluble rHb
accumulation, the most significant improvements in soluble expression
were observed with rHbs containing amino acid substitutions in
beta-globin.
 |
MATERIALS AND METHODS |
Strain and plasmid construction and sequencing.
The strains
and plasmids used in this study are shown in Table
1. In general, strains were constructed
by transforming plasmid DNAs into E. coli strains lacking
plasmids by using the procedure of Chung et al. (5) or
Hanahan (6). Transformants were selected by plating cells
onto Luria-Bertani medium supplemented with 15 µg of tetracycline per
ml and incubating the preparations at 37°C for 12 to 24 h.
pSGE720 contains a synthetic operon composed of the di-
-globin and
Presbyterian-globin genes transcribed from the
tac promoter on a tetracycline-resistant plasmid with the
pUC high-copy-number origin of replication (28).
pSGE728 was constructed by XhoI digestion and deletion from
pSGE720 of one alpha-globin subunit and the di-alpha-globin glycine linker. The resulting plasmid, pSGE726, contained a single alpha-globin gene rather than a di-alpha-globin gene (rHb1.0). The Presbyterian mutation in beta-globin was replaced by digestion with BglII
and HindIII and ligation which introduced wild-type
beta-globin in order to create pSGE728 (rHb0.0). The Presbyterian
mutation in the beta-globin gene of pSGE720 was replaced by digestion
and ligation as described above for pSGE728 in order to introduce wild-type beta-globin and create pSGE733 (di-alpha-globin and wild-type
beta-globin; rHb0.1).
The Providence(asp) mutation (
Lys-82
Asp)
(3) was introduced into the rHb1.1 background to create
rHb9+1.1. The Lys-82
Asp mutation was created by PCR amplification of
a portion of the
-globin gene performed with an oligonucleotide
containing an Asp codon in place of Lys-82 (CBG119;
5'-AGCGAAGGTACCGTCCAGGTT-3') and CBG124
(5'-CCTGACTCCGGAAGAAAAATCC-3'). The PCR product and vector
were digested with BspEI and Asp718 and ligated.
DNA sequencing of plasmids isolated from transformants was performed by
using Sequenase kit reagents and protocols (United States Biochemical Corp.), 33P (Amersham, Inc.), and primers synthesized with
an Applied Biosystems model 380B DNA synthesizer. Sequencing confirmed
the identities of the Providence(asp) and Presbyterian
mutations and that plasmid pSGE767 was transformed into SGE1675 to
produce SGE2782.
The Providence(asp) mutation was introduced into the rHb0.1
background to create rHb9.1. A BamHI-Asp718
fragment from pSGE767 was isolated and ligated into digested pSGE733
(rHb0.1). Sequencing confirmed the identity of the mutation and that
plasmid pSGE768 was transformed into SGE1675 to produce SGE2784 and
into SGE3138 to produce SGE3261. Similar procedures were used to
introduce Providence(asp) and Providence(asp)
plus Presbyterian into a plasmid with a di-alpha-globin Lys-185
Cys
mutation (SGE3083, SGE3084, and SGE3172 [Table 1]).
Fermentations, rHb purification, and analysis.
Fermentations
were performed by using a defined medium in 15-liter Biolaffite
fermentors as described by Looker et al. (17), except that
induction was for 16 h at 28°C (30) unless indicated otherwise. Expression was induced by adding IPTG
(isopropyl-
-D-thiogalactopyranoside) to a concentration
between 10 and 200 µM as indicated below. IPTG was added during the
log phase at an optical density at 600 nm that was approximately
one-third the final cell density (optical density at 600 nm, ~30).
Various concentrations of hemin were added as noted below; typically,
the hemin was distributed into three to five aliquots and added to the
fermentation preparations at 3-h intervals starting at induction.
Different concentrations of hemin did not affect the final cell
densities. When possible, fermentations in which different strains were
compared under the same conditions were performed in parallel to
minimize variability. Purification and functionality were determined as
described by Plomer et al. (23), and norvaline contents were
measured as described by Apostol et al. (1).
Determination of percentages of soluble and insoluble rHb.
We measured the accumulation of soluble and insoluble rHbs for at least
two and usually three or more independent fermentations per condition
examined. One-milliliter samples were withdrawn into 1.7-ml Eppendorf
tubes at appropriate times after induction. These 1-ml samples were
centrifuged in an Eppendorf centrifuge at 4°C for 3 min, and the
supernatants were removed. The pellets were stored at
80°C until
they were assayed. Soluble and insoluble rHb contents were determined
as described previously (30), except that after sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, the rHb was
detected by either silver staining or Western blotting (30).
The gels were silver stained by using the reagents and protocol
recommended by Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan).
Hemin concentration estimation.
The hemin concentration in a
fermentation broth was estimated as follows. Samples of the
fermentation broth were centrifuged, and an aliquot of the supernatant
was added to a solution containing 300 µM human serum albumin
(Baxter) in 50 mM Tris (pH 7.5) such that the concentration of hemin
did not exceed 50 µM. In the presence of excess human serum albumin
hemin forms a 1:1 complex with a well-defined absorbance spectrum
(2), and the hemin concentration was estimated from the
absorbance at 625 nm. By subtracting the new hemin concentration from
the hemin concentration of the previous sample, the quantity of hemin
bound by or taken up by the cells was calculated during the entire time
course of rHb accumulation.
 |
RESULTS |
Improving soluble rHb0.0 accumulation by hemin addition.
In
30°C fermentations containing 15 µM IPTG to induce rHb expression,
the levels of soluble rHb0.0 that accumulated were consistently higher
than the levels of soluble rHb1.1 (averages, 10.0% ± 1.1% and 6.5% ± 1.6% of the of the soluble cell protein for rHb0.0 and rHb1.1,
respectively, in 10 h) (Table 2). At
28°C in the presence of 100 µM IPTG, the accumulation of soluble
rHb0.0 and the accumulation of soluble rHb1.1. increased similarly
(Table 2). Increasing the length of the induction period from 10 to 16 h increased the accumulation of soluble rHb1.1 to 10.9% ± 1.9% of the soluble cell protein but resulted in the yield of soluble rHb0.0 declining from 16.6% ± 0.3% at 10 h after induction to 11.0% ± 0.3% at 16 h after induction (Table 2). The amount of globin remained relatively constant (Table 2), suggesting that there
was a decrease in globin solubility (the proportion of the total globin
present in soluble form).
The possibility that additional heme could support continued soluble
rHb0.0 accumulation was tested by adding hemin two more times, at 9 and
12 h after induction, which increased the final heme concentration
85%, from 0.34 to 0.63 mM. These additions prevented the decline in
the soluble rHb0.0 level observed late in the fermentations described
above. Soluble rHb0.0 accumulated to an average of 19.2% ± 2.1% of
the soluble cell protein, and total globin accumulated to 28.4% ± 8.5% of the soluble cell protein (Table
3). This 75% increase in soluble
hemoglobin accumulation at 16 h after induction was highly
significant (P = 0.0005; as determined by a
t test of the means). Although an increase in the soluble
rHb1.1 accumulation was also observed in fermentations supplemented
with higher levels of heme, the magnitude of the improvement was much
less than the magnitude of the improvement observed with rHb0.0 (Table
3).
Comparison of expression of four rHbs when a higher hemin
concentration was used.
Using the higher hemin concentration (0.63 mM) established for rHb0.0 in 15-liter fermentations at 28°C, we
examined the soluble expression of four different recombinant
hemoglobins in parallel fermentations (Table
4). All four strains were isogenic and
contained identical high-copy-number plasmids except for the following
two globin gene differences: (i) the covalent linkage which forms di-
-globin and (ii) the presence of the
Presbyterian-globin (Asn-108
Lys) mutation.
A significant increase in soluble expression was observed with the two
strains expressing a wild-type
-globin subunit rather than
Presbyterian-globin (P < 0.05 as
determined by multiple-range tests). The average increase in the
soluble rHb level was approximately twofold, from ~10% of the
soluble cell protein to ~20% or more of the soluble cell protein
(Table 4). A slight increase (~7 to 17%) in soluble globin protein
accumulation was correlated with expression of the di-
-globin
subunit with both wild-type and
Presbyterian-globin
subunits, but the sample number was too small to determine statistical significance.
Soluble accumulation of
Lys-82
Asp (Providence) rHb
variants.
Since a mutation in the beta-globin subunit had a
profound negative effect on the soluble expression of a recombinant
hemoglobin, a mutation that improved rather than impaired soluble
expression was sought. One such mutation, Providence(asp)
(Lys-82
Asp), was identified. When coexpressed with di-
-globin
(rHb9.1) (strain SGE2784), this mutation improved the expression of
soluble rHb by 47% to 25.3% ± 5.4% of the soluble cell protein, and
the level of total globin expression increased to 44.4% ± 12.4%
(Table 5). This improvement was apparent
throughout the entire induction period during fermentation (Fig.
1A) and resulted in an average soluble
yield of 3.1 ± 0.7 g/liter. The accumulation of soluble and total
rHb9.1 was significantly greater than the accumulation of soluble and
total rHb0.1 (P < 0.05, as determined by multiple range tests) under identical conditions (Fig. 1A). Addition of the
Providence(asp) mutation to the Presbyterian
-globin
subunit (rHb9+1.1) resulted in a 116% increase in soluble accumulation (Table 5 and Fig. 1A) compared to the soluble accumulation with the
Presbyterian subunit alone (P < 0.02, as determined by
a t test of the means). This rescued rHb1.1 soluble
expression to a level statistically indistinguishable from the level of
wild-type rHb0.1 (Table 5). Molecules that accumulated to higher levels did so in part because a greater proportion of the protein accumulating within the cells remained soluble (Table 5). The rHbs with higher soluble expression levels (Table 5) were correlated with higher total
globin levels (Table 5) (R2 = 0.99) and with higher
percentages of the total globin present as soluble rHb (Table 5)
(R2 = 0.97).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of mutations on soluble rHb accumulation.
Fermentations were incubated at 28°C, induced for 16 h with 100 µM IPTG, and supplemented with hemin (final concentration, 0.63 mM)
at 0, 3, 6, 9, and 12 h after induction. (A) Soluble accumulation
of four variants, rHb0.1 (SGE2706), rHb1.1 (SGE1464), rHb9+1.1
(SGE2782), and rHb9.1 (SGE2784), for 16 h after induction. Most
symbols represent the average from three fermentations; the only
exception is the SGE2782 symbols, which represent the average from five
fermentations. (B) Accumulation of three variants of soluble rHb with a
di- K158C mutations, as described above. Most symbols represents the
average from four fermentations; the only exception is the SGE3083
symbols, which represent the average from two fermentations.
|
|
The presence of the beta-globin mutations had similar effects on
accumulation of a soluble recombinant hemoglobin having a Lys-158
Cys
mutation in di-alpha-globin. The presence of
Providence(asp) improved soluble expression from a maximum
of 11.3% with the Presbyterian beta-globin to 24.4% (Fig. 1C). The
combination of the Providence(asp) and Presbyterian
mutations in beta-globin resulted in an intermediate level of
expression with a maximum of 16.4% soluble globin accumulation (Fig.
1C).
Improving soluble rHb9.1 accumulation by hemin addition.
A
69% increase in the hemin concentration to 1.07 mM significantly
(P = 0.001) increased the rate of soluble rHb9.1
accumulation (strain SGE3261) (Fig. 2A),
and an average of 35.6% ± 2.5% of the soluble cell protein was
soluble rHb9.1. These fermentations resulted in an average soluble
yield of 6.0 ± 0.3 g of rHb9.1 per liter, which was almost
twice the yield (3.1 ± 0.3 g/liter) obtained with the lower heme
concentration (Fig. 2A). The average total rHb9.1 globin accumulation
was 55.6% ± 6.9% of the soluble cell protein, and the total globin
yield from 16-h fermentation was 9.4 g/liter. A maximum accumulation of
soluble rHb9.1 corresponding to 39% of the soluble cell protein and a
maximum total globin accumulation corresponding to 65% of the total
cell protein were observed in an individual fermentation.
Silver-stained gels of the soluble and insoluble fractions of cell
lysates obtained from fermentations contained prominent di-
-globin
and
Providence(asp)-globin bands that accounted for
the majority of the protein in each of the lysate fractions (Fig. 2B).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
rHb9.1 accumulation. (A) Soluble rHb9.1 (SGE3261)
fermentation yields under two different heme conditions and with two
different lengths of induction. Symbols: , average soluble rHb9.1
concentrations obtained with the original heme concentration (0.63 mM);
, average soluble rHb9.1 concentrations in three fermentations
supplemented with heme (final concentration, 1.07 mM) at 0, 3, 6, 9, and 12 h; , soluble rHb9.1 concentrations in four fermentations
induced for 24 h and supplemented with eight aliquots of hemin
(final concentration, 1.71 mM). (B) Globin protein from soluble and
insoluble cell lysate fractions from one of the SGE3261 fermentations
in panel A induced for 24 h. The globin bands are indicated by the
arrows (upper arrow, di- -globin; lower arrow, -globin). Lane S,
soluble lysate fraction; lane I, insoluble lysate fraction.
|
|
Extending the induction period to 24 h and adding hemin every
3 h resulted in a marginal increase in the average soluble rHb9.1 yield, from 6.0 ± 0.3 to 6.4 ± 0.2 g/liter, but did not
result in any increase in the percentage of soluble or total rHb9.1
(Fig. 2A). However, this treatment resulted in the highest yield of soluble rHb9.1 from an individual fermentation (6.8 g/liter). We also
tested the effect on soluble rHb9.1 accumulation of adding at induction
the entire amount of hemin typically distributed over the entire
fermentation period. We observed no significant difference in the
soluble rHb9.1 accumulation when this strategy was used.
Heme-to-rHb9.1 stoichiometry.
The molar concentration of hemin
was compared to the molar accumulation of soluble rHb9.1 on a per heme
basis. The molar concentration of soluble rHb9.1 was calculated from
the soluble yields. The molar concentration of hemin supplied was
calculated from the known mass of hemin added. One mol of hemoglobin
contains 4 mol of globin subunits (2 mol of
subunits and 2 mol of
subunits), and each globin subunit accommodates heme; therefore, 1 mol of hemoglobin contains 4 mol of heme. The accumulation of soluble rHb9.1 was strongly correlated with the concentration of hemin supplied, and there was an apparently linear relationship up to a hemin
concentration of about 1 mM (Fig. 3A).
Addition of hemin to a concentration of >1 mM did not improve the
soluble rHb9.1 accumulation, indicating that hemin was not limiting
under these conditions (Fig. 3A). The correlation between the
accumulation of soluble rHb9.1 subunits and the concentration of hemin
supplied was very strong over the initial concentration range used
(Fig. 3A) (R2 = 0.90; 50 samples). The comparison revealed
that an approximately threefold molar excess of hemin was required for
accumulation of soluble rHb9.1 over a range of concentrations (Fig.
3A). We did not observe a single sample among the 70 samples examined that was accompanied by less than a 2.5-fold molar excess of hemin (Fig. 3A). This value was therefore considered the lower limit of hemin
excess required for maximal soluble rHb9.1 accumulation.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Comparison of accumulation of soluble rHb9.1 heme
sites with the concentration of hemin supplied. The symbols represent
70 individual samples. One heme site is present in each subunit and
subunit; therefore, there are four sites per hemoglobin molecule.
The heavy line represents a threefold molar excess of hemin with
respect to heme binding sites in hemoglobin. The light line represents
a 2.5-fold molar excess of hemin. (B) Hemin uptake and hemoglobin
production. Symbols: , independent measurements of hemin loss from
the fermentation broth; , time course for rHb production converted
to the amount of hemin required for each level of rHb accumulation,
assuming that there are four heme molecules per rHb molecule.
|
|
To determine the relative importance of time of accumulation and hemin
concentration, we compared two sets of data from different hemin
supplementation experiments in which the concentrations of hemin were
nearly identical at different times during accumulation. In one
experiment a total of 0.64 mM hemin was added by 6 h after induction, and in the other experiment 0.63 mM hemin was added by
12 h after induction. We compared the concentrations of soluble rHb9.1 on a per heme basis at 8 h after induction in the first experiment and at 14 and 16 h after induction in the second
experiment. Regardless of the time since induction, the soluble rHb9.1
accumulations were indistinguishable (0.22 ± 0.02 and 0.19 ± 0.04 mM, respectively), suggesting that under the conditions used
hemin was more important than time of rHb accumulation for achieving
high soluble yields.
We examined the heme lost from the medium in the 15-liter fermentor
incubated at 28°C in which rHb1.1 expression was induced by adding
100 µM IPTG and correlated it with the accumulation of soluble rHb.
An approximately stoichiometric relationship was observed, indicating
that only the heme required to support soluble rHb accumulation
disappeared from the medium (Fig. 3B).
Accumulation of soluble rHb0.1 in heme-free fermentations.
We
tested whether rHb0.1 accumulated to higher soluble levels than rHb1.1
accumulated in fermentations without hemin. When two fermentations were
incubated at 28°C and induced with 100 µM IPTG, the average soluble
rHb0.1 yield was just 2.5% ± 0.2% of the soluble cell protein, a
value similar to the value of obtained for rHb1.1 (26). When
10 µM IPTG was used for induction, an average of 1.6% ± 0.3% of
the soluble cell protein was soluble rHb0.1. By dividing the soluble
rHb0.1 accumulation in the absence of hemin by the accumulation in the
presence of hemin, we estimated that a maximum of 12 to 15% of the
accumulation in the presence of hemin was due to E. coli
heme biosynthesis.
Functionality of rHbs.
Samples of six variants of recombinant
hemoglobins were purified. Two parameters of functionality, oxygen
binding affinity and cooperativity, were measured (Table
6). As expected, the hemoglobin mutations
affected oxygen binding in the recombinant molecules to approximately
the same degree that they affected oxygen binding in the native
hemoglobin molecules (3, 21). The correlations between the
two functional parameters and between each parameter and the soluble
expression levels were examined. The two functional parameters were not
correlated with each other (R2 = 0.04; P = 0.69). In spite of this, these parameters were equally correlated
with soluble expression (R2 = 0.46 for oxygenbinding
affinity [P = 0.14] and R2 = 0.47 for
cooperativity [P = 0.13]). This indicates that low oxygen binding affinity and/or cooperativity may be correlated with
higher soluble expression. However, since the P values were greater than 0.1, the correlation was not statistically significant, and additional testing would be required to verify this observation.
In addition, a sample of soluble rHb9.1 from a fermentation yielding
3.7g/liter was examined for norvaline substitution, which was observed
previously in rHb1.1 (1, 27). The level of norvaline was
below the limit of quantitation, indicating that high-level soluble
expression did not increase the level of misincorporation of this amino acid.
 |
DISCUSSION |
Measurements of the insoluble protein contents in fermentations
yielded evidence that reductions in soluble hemoglobin levels were due
to conversion into insoluble globin. Loss of heme as a mechanism for
turnover of soluble hemoglobin into insoluble globins has been
well-characterized (20). The rate of turnover was consistent
with an 11-h half-life for rHb1.1. in E. coli flask cultures
(28), raising the possibility that when heme became limiting
(when the level dropped below a required stoichiometric level), soluble
accumulation ceased and turnover of rHb was driven primarily by heme
loss, followed by insoluble aggregation.
Many unstable human hemoglobin mutants that were found in vivo in
inclusion bodies contained heme, as did in vitro heat-precipitated forms of mutant hemoglobins (24). Heme may stabilize some
globin conformations even in insoluble aggregates, and the absence of heme from one or more of the four hemoglobin subunits may lead to
insolubility and rapid turnover of the subunits (28).
Although globin can accept heme before it is released from the ribosome in eukaryotic cell-free translation systems (15), it is
unclear whether this occurs in bacteria. Unlike the situation in
eukaryotes, globin probably cannot complete folding into its native
configuration until it is released from the ribosome in E. coli (22). Therefore, without heme, apo-globin can be
likened to a trapped folding intermediate.
In fermentations supplemented with increased heme, several globin
variants exhibited greater soluble hemoglobin accumulation than seen
with rHb1.1. The abilities of different globins to accumulate to
different levels may be understood in terms of the stability of the
apo-globin. In myoglobin, the levels of expression of a series of
mutants were shown to be related to the stability of the folded
apo-globin (7, 8). Thus, the rate of formation of functional
myoglobin or hemoglobin is a function of the concentration of heme and
the concentration of apo-globin in a classical bimolecular manner (Fig.
4).

View larger version (7K):
[in this window]
[in a new window]
|
FIG. 4.
A simplified reaction for the formation of hemoglobin.
The reversible biomolecular reaction combining apoglobin and heme
depends on the concentration of the reactants (concentration denoted by
brackets). Irreversible aggregants compete as side reactions, and the
concentration of the reactant heme inside the cell is driven by the
extracellular heme concentration.
|
|
The reversible bimolecular reaction combining apo-globin and heme to
form hemoglobin can best be encouraged by increasing the concentration
of one or both reactants, but this reaction competes with aggregation
of apo-globin, a terminal side reaction. Either hemoglobin can
aggregate into insoluble hemoglobin that still contains heme or
dissociation of heme from one or more subunits may be a prerequisite.
Accumulation of soluble hemoglobin is very sensitive to (i) the rate of
globin synthesis, (ii) the heme pool within the cells, and (iii) the
stability of the apo-globin (30), as discussed below.
In each experiment in this study, the expression strains and plasmids
were identical, as were the fermentation and induction conditions.
Therefore, approximately the same amount of protein synthesis occurred
for each rHb variant. No significant differences in cell growth were
observed, suggesting that the rHb variants did not have different toxic
effects on the cells, which could have accounted for the differences in
the percentages of the soluble protein accumulating as soluble rHb.
The extracellular heme concentration was manipulated in order to
influence the intracellular heme concentration. The use of identical
expression strains imposed the same heme transport (diffusion) and
biosynthetic capacities on the cells expressing all rHb variants. The
E. coli strains were sufficiently heme permeable to allow a
heme protein, rHb9.1, to accumulate to levels that were equivalent to
almost 40% of the soluble protein in the cell. Since very high soluble
expression of rHbs always required a >2.5-fold molar excess of heme,
this excess may be required for sufficient diffusion across the cell
membrane to maintain an intracellular heme concentration high enough to
drive the bimolecular reaction of heme with globin. Fermentations not
supplemented with heme accumulated only ~12 to 15% of the soluble
rHb0.1 accumulated when hemin was added, indicating that biosynthesis
of heme contributes little to the soluble globin and therefore to the
heme pool within the cells. In addition, exogenous hemin probably
suppresses endogenous heme production in E. coli, so the
actual contribution of endogenous heme to soluble rHb accumulation is
probably much less than the estimated contribution.
Mutations which influence protein solubility were presumed to affect
apo-globin stability and therefore, concentration by reducing the
terminal aggregation side reaction of apo-globin. More than 29% the
more than 200 human hemoglobin beta-chain variants investigated
previously were unstable (4). Instability of hemoglobin protein containing the Presbyterian mutation has been observed previously (14). This instability probably had an impact on the accumulation of soluble rHb1.1 in E. coli, which was
approximately one-half the accumulation of rHb0.1 containing wild-type
Asn-108 instead of lysine. With the Presbyterian mutant, the apo-globin aggregation reaction most likely dominates the soluble accumulation rate (30). However, no significant difference in the
stabilities of these globin proteins was observed in the gas phase by
mass spectroscopy (1a).
The Providence(asp) mutation occurs at a key residue in the
DPG binding cleft (Lys-82; EF6) between the two beta-globin subunits in
the hemoglobin tetramer (Fig. 5). This
anion-binding cleft is lined with at least six positively charged
residues, three from each beta-globin (His-2, His-143, and Lys-82). In
the absence of DPG or inositol hexaphosphate, such as during
accumulation of rHbs in E. coli, electrostatic repulsion
between these residues may destabilize or even partially denature the
beta-globin structure. Replacement of the normally occurring positively
charged lysine by a negatively charged aspartate introduces a
counterion into the DPG pocket, which may form an electrostatic
interaction with His-143 (3), which is likely to stabilize
the beta chain. This could account for the improved accumulation of
soluble rHb9.1 compared with the accumulation of soluble rHb0.1, which
contains the wild-type lysine at position 82. The charge substitution
may also increase the rate of hemoglobin assembly by reducing the electrostatic repulsion in this region. Differences in accumulation of
stable hemoglobin variants in humans appear to be correlated with
differences in subunit assembly rates (4).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 5.
Principal amino acids in the DPG binding pocket at the
interface between the two beta subunits ( 1 and 2). (A) Native
hemoglobin with a lysine at position 82. (B) Hemoglobin
Providence(asp) with an aspartate at position 82. The
positions of the amino acids in -globin are indicated; the
designations in parentheses are helical structure designations. The
interface between the two subunits is indicated by a dashed
diagonal line.
|
|
It is likely that the same Lys-82
Asp (Providence) substitution could
stabilize and improve the accumulation of other soluble recombinant
hemoglobin molecules, since all such molecules are typically
expressed without DPG present. This was observed with a di-
-globin
mutant rHb, Lys-158
Cys, in which the presence of Providence(asp) more than doubled the soluble
globin accumulation. The addition of the
Providence(asp) mutation to rHb1.1 to create rHb9+1.1
resulted in a more than twofold increase in soluble expression, rescuing the Presbyterian mutation by restoring the soluble expression to wild-type levels. In addition to improving soluble globin
accumulation, rHb variants also increased total globin accumulation.
This implied that soluble hemoglobin is more stable than the insoluble
protein; otherwise, an improvement in solubility would not be expected to increase the total globin levels but merely would reallocate more of
the total globin to the soluble form. Our interpretation is consistent
with the results of pulse-chase experiments in which we observed a much
shorter half-life for insoluble globin than for soluble globin
(28). Thus, the greater the amount of globin maintained in
the soluble form, the greater the total globin accumulation expected,
since the insoluble globin is more rapidly removed.
The rHb affinity for heme theoretically could contribute to the
difference in soluble rHb accumulation by eliminating or reducing the
denaturation of hemoglobin to apo-globin plus heme. While the stability
of myoglobin (and by analogy, hemoglobin) depends on the affinity for
heme (7), this does not necessarily apply to the forward
reaction (i.e., folding and hemoglobin formation). High rates of heme
loss from myoglobin were not necessarily correlated with unstable
apo-globin and vice versa (8). Although the
Providence(asp) mutation resulted in a lower oxygen
affinity, this was most likely due to stabilization of the T-state (low
affinity) of hemoglobin in the absence of DPG, not to changes in the
heme pocket (3). Because of their location relative to the
heme pocket, we do not believe that the mutations studied here affected
soluble expression because of significant changes in heme affinity.
This study demonstrated that increases in accumulation of soluble
mutant rHbs were correlated with increases in the proportion of rHb
accumulating as soluble protein rather than insoluble protein. This
supports the model in which mutations reduced the terminal aggregation
side reaction and thus increased the soluble yield. Increased heme
supply supported higher soluble yields of mutant rHbs, which
corroborated the bimolecular reaction model. In this study using rHbs,
we obtained what we believe are the highest soluble expression yields
for a heterogous, complex, multiple-subunit protein with a prosthetic
group (heme) ever obtained in E. coli (6.4 g/liter).
Maintenance of a threefold molar excess of heme was critical to
accumulation of soluble globin. Our study confirmed that rHbs can be
very significantly overproduced in E. coli. In addition, the
results of the study of recombinant hemoglobin mutants provide new and
useful model for the effects of mutations on protein folding and
subunit assembly.
 |
ACKNOWLEDGMENTS |
The assistance of Izydor Apostol in purification, functionality
measurements, and especially norvaline measurements was invaluable. Michael Schick supplied the anti-rHb1.1 antibody for Western blotting, Louise Lucast synthesized the oligonucleotides required to make rHb
mutants, Antony Mathews provided the hemin uptake assay to R.B., and
Shawn Curry introduced M.P. to insoluble Western blotting and performed
several of the initial measurements. We appreciate the technical
assistance and/or helpful comments of many individuals in the Somatogen
Molecular Biology, Assay Services, and Pilot Operations groups and the
contributions of strains or plasmids by Jeff Davidson, Louise Lucast,
and Elaine Best. We appreciate the stimulating discussions which we had
with John Olson, Antony Mathews, and Doug Lemon and the helpful
comments on the manuscript provided by Doug Looker, Izydor Apostol, and
Antony Mathews.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Inhale
Therapeutic Systems, 150 Industrial Rd., San Carlos, CA 94070-6256. Phone: (650) 631-3489. Fax: (650) 631-3150.
Present address: Department of Molecular, Cellular, and
Developmental Biology, University of Colorado, Boulder, CO
80309-0347.
 |
REFERENCES |
| 1.
|
Apostol, I.,
J. Levine,
J. Lippincott,
J. Leach,
E. Hess,
C. R. Glascock,
M. J. Weickert, and R. Blackmore.
1997.
Incorporation of norvaline at leucine positions in recombinant human hemoglobin expressed in Escherichia coli.
J. Biol. Chem.
272:28980-28988[Abstract/Free Full Text].
|
| 1a.
| Apostol, I. Personal communication.
|
| 2.
|
Beaven, G. H.,
S.-H. Chen,
A. d'Albis, and W. B. Gratzer.
1974.
A spectroscopic study of the haemin-human-serum-albumin system.
Eur. J. Biochem.
41:539-546[Medline].
|
| 3.
|
Bonaventura, J.,
C. Bonaventura,
B. Sullivan,
G. Ferruzzi,
P. R. McCurdy,
J. Fox, and W. F. Moo-Penn.
1976.
Hemoglobin Providence. Functional consequences of two alterations of the 2,3-diphosphoglycerate binding site at position 82.
J. Biol. Chem.
251:7563-7571[Abstract/Free Full Text].
|
| 4.
|
Bunn, E. H., and B. G. Forget.
1986.
Hemoglobin: molecular, genetic and clinical aspects. W. B.
Saunders Co., Philadelphia, Pa.
|
| 5.
|
Chung, C.,
S. Niemela, and R. Miller.
1989.
One step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution.
Proc. Natl. Acad. Sci. USA
86:2172-2175[Abstract/Free Full Text].
|
| 6.
|
Hanahan, D.
1985.
Techniques for transformation of E. coli, p. 109-135.
In
D. M. Glover (ed.), DNA cloning: a practical approach., vol. 1. IRL Press, Oxford, United Kingdom.
|
| 7.
|
Hargrove, M. S.,
D. Barrick, and J. Olson.
1996.
The association rate constant for heme binding to globin is independent of protein structure.
Biochemistry
35:11293-11299[Medline].
|
| 8.
|
Hargrove, M. S.,
S. Krzywda,
A. J. Wilkinson,
Y. Dou,
M. Ikeda-Saito, and J. Olson.
1994.
Stability of myoglobin: a model for the folding of heme proteins.
Biochemistry
33:11767-11775[Medline].
|
| 9.
|
Hart, R. A.,
P. T. Kallio, and J. E. Bailey.
1994.
Effect of biosynthetic manipulation of heme on insolubility of Vitreoscilla hemoglobin in Escherichia coli.
Appl. Environ. Microbiol.
60:2431-2437[Abstract/Free Full Text].
|
| 10.
|
Hoffman, S. J.,
D. L. Looker,
J. M. Roehrich,
P. E. Cozart,
S. L. Durfee,
J. L. Tedesco, and G. L. Stetler.
1990.
Expression of fully functional tetrameric human hemoglobin in Escherichia coli.
Proc. Natl. Acad. Sci. USA
87:8521-8525[Abstract/Free Full Text].
|
| 11.
|
Jessen, T. H.,
N. H. Komiyama,
J. Tame,
J. Pagnier,
D. Shih,
B. Luisi,
G. Fermi, and K. Nagai.
1994.
Production of human hemoglobin in Escherichia coli using cleavable fusion protein expression vector.
Methods Enzymol.
231:347-364[Medline].
|
| 12.
|
Kery, V.,
D. Elleder, and J. P. Kraus.
1995.
-Aminolevulinate increases heme saturation and yield of human cystathionine -synthase expressed in Escherichia coli.
Arch. Biochem. Biophys.
316:24-29[Medline].
|
| 13.
|
King, J.,
C. Haase-Pettingell,
A. S. Robinson,
M. Speed, and A. Mitraki.
1996.
Thermolabile folding intermediates: inclusion body precursors and chaperone substrates.
FASEB J.
10:57-66[Abstract].
|
| 14.
|
Kohne, E.,
L. J. Behnken,
D. Leupold,
H. Rogge,
H. Martin, and E. Kleihauer.
1979.
Hemoglobin Presbyterian [ 108 (G10) asn lys] in a German family.
Hemoglobin
3:365-370[Medline].
|
| 15.
|
Komar, A. K.,
A. Kommer,
I. A. Krasheninnikov, and A. S. Spirin.
1997.
Cotranslational folding of globin.
J. Biol. Chem.
272:10646-10651[Abstract/Free Full Text].
|
| 16.
|
Leutzinger, Y., and S. Beychock.
1981.
Kinetics and mechanism of heme-induced refolding of human alpha-globin.
Proc. Natl. Acad. Sci. USA
78:780-784[Abstract/Free Full Text].
|
| 17.
|
Looker, D.,
A. J. Mathews,
J. O. Neway, and G. L. Stetler.
1994.
Expression of recombinant human hemoglobin in Escherichia coli.
Methods Enzymol.
231:364-374[Medline].
|
| 18.
|
Looker, D. L.,
D. Abbott-Brown,
P. Cozart,
S. Durfee,
S. Hoffman,
A. J. Mathews,
J. Miller-Roehrich,
S. Shoemaker,
S. Trimble,
G. Fermi,
N. H. Komiyama,
K. Nagai, and G. L. Stetler.
1992.
A human recombinant haemoglobin designed for use as a blood substitute.
Nature
356:258-260[Medline].
|
| 19.
|
Miller, J. H.
1972.
Experiments in molecular genetics.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 20.
|
Mitraki, A., and J. King.
1989.
Protein folding intermediates and inclusion body formation.
Bio/Technology
7:690-697.
|
| 21.
|
Moo-Penn, W. F.,
J. A. Wolff,
G. Simon,
M. Vacek,
D. L. Jue, and M. H. Johnson.
1978.
Hemoglobin Presbyterian: 108 (G10) asparagine lysine. A hemoglobin variant with low oxygen affinity.
FEBS Lett.
92:53-56[Medline].
|
| 22.
|
Netzer, W. J., and F. U. Hartl.
1997.
Recombination of protein domains facilitated by co-translational folding in eukaryotes.
Nature
388:343-349[Medline].
|
| 23.
|
Plomer, J. J.,
J. R. Ryland,
M-A. H. Matthews,
D. Traylor,
E. E. Milne,
S. L. Durfee,
A. J. Mathews, and J. O. Neway.
May 1996.
Purification of hemoglobin. International Patent Application PCT WO96/15151
.
|
| 24.
|
Rachmilewitz, E. A.
1974.
Denaturation of the normal and abnormal hemoglobin molecule.
Semin. Hematol.
11:441-462[Medline].
|
| 25.
|
Schein, C. H.
1989.
Production of soluble recombinant proteins in bacteria.
Bio/Technology
7:1141-1149.
|
| 26.
|
Verderberg, E.,
L. Lucast,
J. A. VanDehy,
P. Cozart,
J. B. Etter, and E. A. Best.
1997.
Role of the hemA gene product and -aminolevulinic acid in regulation of Escherichia coli heme synthesis.
J. Bacteriol.
179:4583-4590[Abstract/Free Full Text].
|
| 27.
|
Weickert, M. J., and I. Apostol.
1998.
High-fidelity translation of recombinant human hemoglobin in Escherichia coli.
Appl. Environ. Microbiol.
64:1589-1593[Abstract/Free Full Text].
|
| 28.
|
Weikert, M. J., and S. R. Curry.
1997.
Turnover of recombinant human hemoglobin in Escherichia coli occurs rapidly for insoluble and slowly for soluble globin.
Arch. Biochem. Biophys.
348:337-346[Medline].
|
| 29.
|
Weickert, M. J.,
D. H. Doherty,
E. A. Best, and P. E. Olins.
1996.
Optimization of heterologous protein production in Escherichia coli.
Curr. Opin. Biotechnol.
7:494-499[Medline].
|
| 30.
|
Weickert, M. J.,
M. Pagratis,
S. R. Curry, and R. Blackmore.
1997.
Low temperature improves accumulation of soluble recombinant hemoglobin in Escherichia coli by stabilization of apo-globin.
Appl. Environ. Microbiol.
63:4313-4320[Abstract].
|
| 31.
|
Wetzel, R.
1994.
Mutations and off pathway aggregation of proteins.
Trends Biotechnol.
12:193-198[Medline].
|
| 32.
|
Woodward, S. I., and H. A. Dailey.
1995.
Regulation of heme biosynthesis of Escherichia coli.
Arch. Biochem. Biophys.
316:110-115[Medline].
|
Applied and Environmental Microbiology, February 1999, p. 640-647, Vol. 65, No. 2
0099-2240/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Villarreal, D. M., Phillips, C. L., Kelley, A. M., Villarreal, S., Villaloboz, A., Hernandez, P., Olson, J. S., Henderson, D. P.
(2008). Enhancement of Recombinant Hemoglobin Production in Escherichia coli BL21(DE3) Containing the Plesiomonas shigelloides Heme Transport System. Appl. Environ. Microbiol.
74: 5854-5856
[Abstract]
[Full Text]
-
Apostol, I., Brooks, P. D., Mathews, A. J.
(2001). Application of high-precision isotope ratio monitoring mass spectrometry to identify the biosynthetic origins of proteins. Protein Sci.
10: 1466-1469
[Abstract]
[Full Text]